lantheus 产品代理
lantheus 产品代理
Lantheus总部位于马萨诸塞州北比利卡，在新泽西州、加拿大和瑞典设有办事处。该公司在全球拥有600多名员工。
我们的产品
我们的产品通常用于诊断或治疗冠心病（CAD）、充血性心力衰竭（CHF）、中风、癌症和其他疾病。
除了我们多样化的商业化成像剂和产品组合外，我们还拥有强大的开发渠道，利用正电子发射断层扫描（PET）技术，开发内部发现的下一代一流成像剂，重点是增强当前的成像模式，满足未满足的诊断医学成像需求。
随着祖细胞加入Lantheus家族，我们在肿瘤学领域增加了一系列放射疗法、靶向PET显像剂和小分子疗法。
DEFINITY®
PYLARIFY
TechneLite®
Xenon-133
AZEDRA®
NEUROLITE®
Thallium-201
Cardiolite®
Gallium-67
Lantheus is a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products that help healthcare professionals identify disease and improve patient treatment and care. Our pioneering products assist physicians in the diagnosis and treatment of conditions affecting the heart, brain, lungs and other organs using echocardiography, nuclear imaging, radiotherapeutics, and targeted PET imaging agents.
Lantheus is headquartered in North Billerica, Massachusetts with offices in New Jersey, Canada, and Sweden. The company has more than 600 employees worldwide.
Our Products
Our products are routinely used for diagnosis or treatment of coronary artery disease (CAD), congestive heart failure (CHF), stroke, cancer and other diseases.
In addition to our diversified portfolio of commercialized imaging agents and products, we have a strong development pipeline of internally-discovered next generation, first-in-class imaging agents, using positron emission tomography (PET), focused on enhancing current imaging modalities and fulfilling unmet diagnostic medical imaging needs.
As Progenics joined the Lantheus family, we added a pipeline of radiotherapeutics, targeted PET imaging agents and small molecule therapeutics in the oncology space.
